Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
NCT ID: NCT01940172
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-491
This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Approximately 30 to 40 subjects will be administered a combination of conatumumab and birinapant. In the initial dose-escalation stage of the study, adult female subjects will receive conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to determine the MTD of birinapant when administered with a fixed dose of conatumumab. In safety expansion stage, adult female subjects will receive conatumumab in combination with birinapant at the MTD of the combination.
Massachusetts General Hospital, Dana-Farber Cancer Institute
Michael Birrer, MD, PhD,
Massachusetts General Hospital
Susana Campos, MD,
Dana-Farber Cancer Institute
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute:
Christin Whalen, 617-582-7738,
Inclusion Criteria-If subject:
- Is a women who is at least 18 years of age.
- Has a negative serum pregnancy test at screening for women of childbearing potential.
- Pathologically confirmed ovarian cancer (epithelial ovarian cancer, primary
peritoneal cancer, or fallopian tube cancer) that are second line platinum resistant
or platinum sensitive subjects who are unable to receive further platinum based
therapy. Subjects may have had a maximum of 3 prior systemic chemotherapies
(excluding hormonal therapies and investigational agents).
- Has a performance status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG)
- Has a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
1.1 criteria AND meet Gynecologic Cancer InterGroup (GCIG) CA 125 criteria.
- Consents to a mandatory tumor sampling (biopsy or ascites) attempt for both
pre-treatment and post-treatment research sampling.
- Has a life expectancy of at least 3 months.
- Has adequate liver, renal, pancreatic, coagulation and bone marrow function.
- Has a FcγRIIIa subtype of high/intermediate-affinity defined by polymorphism of V/V
or V/F and not F/F amino acids in receptors. (FOR EXPANSION PHASE ONLY)
Exclusion Criteria-If subject:
- Has cancer that progresses within 6 months of completion of first line platinum-based
- Has symptomatic or uncontrolled brain metastases requiring current treatment (<8
weeks from last cranial radiation treatment or <4 weeks from last steroid treatment).
- Has known intolerance to any of the study drugs or any of their excipients.
- Has known or suspected diagnosis of human immunodeficiency virus (HIV) or chronic
active Hepatitis B or C.
- Has uncontrolled hypertension defined as blood pressure >160/100 mmHg without
medication, or not controlled despite medications.
- Has received systemic chemotherapy, hormonal therapy, immunotherapy, anti-tumor
necrosis factor (TNF) therapies, experimental or approved anticancer
≤28 days before enrollment.
- Has impaired cardiac function or clinically significant cardiac disease including the
1. New York Heart Association Grade III or IV congestive heart failure.
2. Myocardial infarction within the last 12 months prior to dosing with birinapant.
- Has a QT interval corrected for heart rate (QTcB) >480 msec (including subjects on
medication). Subjects with a ventricular pacemaker for whom QT interval is not
measurable may be eligible.
- Has a lack of recovery of prior adverse non-hematological events to Grade ≤1 severity
(National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE]
v4.03) (except alopecia) due to therapy administered prior to the initiation of study
- Has any concurrent disease and/or medical condition that, in the opinion of the
Investigator, would prevent the subject's participation, render the subject at
excessive risk (including excessive risks due to the toxicity profile of the planned
combination chemotherapeutic regimen), or limit the subject's compliance with the
protocol's required evaluations.
- Has a prior history of cranial nerve palsy.
- Has autoimmune diseases or inflammatory diseases, for example, active rheumatoid
arthritis, active inflammatory bowel disease or any chronic inflammatory conditions.
- Has pseudomyxoma, mesothelioma, unknown primary tumor, sarcoma, neuroendocrine
histology, clear cell or mucinous histology or subjects with borderline ovarian
- Requires concomitant chronic use of anti-TNF therapies, corticosteroids or
nonsteroidal anti- inflammatory drugs (NSAIDS). Intermittent use (7 or fewer days per
14 days) of corticosteroids as pre-medications is allowed.